COMP <GO>
PBM vs KYNB // GROSS PROFIT MARGIN
Psyence Biomedical Ltd. (NASDAQ) VS. Kyntra Bio Inc. (NASDAQ) • 15-METRIC TALLY: PBM 2
— KYNB 0
■ METRIC PARITY
LAST: $3.61 (+6.18%) • MKT CAP: $19.2M
gross-margins
—
LAST: $4.65 (-1.48%) • MKT CAP: $18.8M
gross-margins
91.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBM VS. KYNB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBM | KYNB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 91.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 68.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -65.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.4 | 29.5 | +10.90 | PBM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $19.2M | $18.8M | $361.0K | PBM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBM REV | KYNB REV | PBM GROSS % | KYNB GROSS % | PBM FCF | KYNB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $6.4M | — | 91.4% | — | -$4.8M |
| FY 2024 | — | $29.6M | — | 47.5% | — | -$138.3M |
| FY 2023 | — | $46.8M | — | — | — | -$315.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBM // BETA —
KYNB // BETA —